Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Cheng

Internal Medicine Columbia, MD Medical Doctor

NPI 1437125515 CMS profile 337017

5450 Knoll North Dr, Suite 260, Columbia, MD 21045

Open in the dashboard

General payments

$2,809

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Cheng of Columbia, MD is reported in the CMS Open Payments database as having received $2,809 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $649 32
2024 General $78 4
2023 General $38 2
2021 General $394 24
2020 General $222 15
2019 General $1,428 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Cheng
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Peter Cheng were reported at $649. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Peter Cheng Internal Medicine median Middle half National median
2019 $1,428 $159 $48–$570 $163
2020 $222 $119 $33–$402 $114
2021 $394 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $38 $149 $45–$519 $160
2024 $78 $154 $47–$537 $164
2025 $649 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $509 24 payments
  2. Janssen Pharmaceuticals, Inc $508 23 payments
  3. Lilly USA, LLC $496 31 payments
  4. Pfizer Inc. $317 22 payments
  5. Amgen Inc. $170 11 payments
  6. Novo Nordisk Inc $162 9 payments
  7. Merck Sharp & Dohme Corporation $93 6 payments
  8. GlaxoSmithKline, LLC. $84 5 payments
  9. AbbVie, Inc. $61 3 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $43 3 payments
  11. Other $366 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,789 156 payments
  2. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $288 20 payments
  2. JARDIANCE $238 16 payments
  3. INVOKANA $220 3 payments
  4. ZEPBOUND $204 10 payments
  5. MOUNJARO $185 9 payments
  6. XIGDUO $183 8 payments
  7. CHANTIX $163 11 payments
  8. FARXIGA $163 6 payments
  9. Ozempic $162 9 payments
  10. TRULICITY $134 9 payments
  11. Other $1,842 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

6,847

Median for Internal Medicine: 777

Drug cost

$442,291

Median for Internal Medicine: $73,373

Branded share of claims

13.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 78 $91,776
Eliquis Apixaban Brand 70 $74,848
Ozempic Semaglutide Brand 30 $73,176
Mounjaro Tirzepatide Brand 19 $27,666
Xarelto Rivaroxaban Brand 27 $25,910
Januvia Sitagliptin Phosphate Brand 19 $24,753
Farxiga Dapagliflozin Propanediol Brand 11 $14,040
Atorvastatin Calcium Generic 729 $10,043
Metoprolol Succinate Generic 307 $6,479
Amlodipine Besylate Generic 670 $5,096

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$269,414

Of which drugs: $97,348

Medicare patients

667

Average age 77

Services billed

9,247

318 women, 349 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 36%
Diabetes 34%
Chronic kidney disease 22%
Ischemic heart disease 18%
Cancer 18%
Depression 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 28 2,280 $45,721
Pcv20 vaccine im 90677 Office 103 103 $29,763
Sarscv2 vac 30mcg trs-suc im 91320 Office 78 80 $12,004
Vaccine for influenza for injection into muscle 90662 Office 109 109 $8,849

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $31
$31 19 —
ZEPBOUND
  • Lilly USA, LLC $31
$31 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $3
$3 — —
GARDASIL
  • Merck Sharp & Dohme Corporation $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record